The adrafül product described in the original article combined adrafinil with caffeine and theanine. Adrafinil makes this a materially different review from an ordinary caffeine or nutritional supplement.
Page Contents
Formula recorded in the original review
The following table is retained as an archival record, not a verified current label or dosing recommendation. Match a present bottle to its own label; a changed or unavailable source does not establish that a product is discontinued.
adrafül Ingredients |
| Ingredients |
| L-Theanine, Adrafinil (150 mg), Caffeine (100 mg) |
What the old record shows
The archive identifies 150 mg adrafinil and 100 mg caffeine, with theanine but no amount given for it. These are historical label details, not a regimen or an endorsement of use. A current manufacturer panel was not verified.
Do not infer that a familiar caffeine/theanine pairing makes the third component safe. The combined effect and risks need their own evidence.
Regulatory context
FDA’s 2019 warning letter to Peak Nootropics addressed adrafinil and other products as unapproved drugs and explained that the products were not dietary supplements or conventional foods. That is relevant context, not a claim that this exact brand received the letter.
Online availability or a supplement-style package cannot establish lawful marketing or appropriate personal use. The country, substance and activity matter; see the legality guide.
Why the old endorsement is withdrawn
The original review’s personal experience and performance language could normalize an experimental drug combination. A subjective report cannot establish safety, durable benefit or a suitable dose for readers.
Adding caffeine increases the importance of considering the whole exposure. Theanine should not be described as a protective ingredient that cancels risks. This page supplies no sourcing instructions or self-experiment schedule.
Conclusion
This archive is useful for identifying what an older reference meant by adrafül. It is not a buying recommendation. The missing current verification and the adrafinil regulatory issue are substantive limitations, not minor footnotes beneath a positive verdict.
If a person has taken the product and is experiencing concerning symptoms, seek medical advice with the package details. Persistent sleepiness or concentration problems should be assessed rather than managed through an unapproved-drug stack.
